Cleo Diagnostics Ltd (COV) - Total Liabilities
Based on the latest financial reports, Cleo Diagnostics Ltd (COV) has total liabilities worth AU$1.14 Million AUD (≈ $803.21K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Cleo Diagnostics Ltd (COV) equity growth momentum to track the company's year-over-year net asset growth rate.
Cleo Diagnostics Ltd - Total Liabilities Trend (2022–2025)
This chart illustrates how Cleo Diagnostics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Cleo Diagnostics Ltd Competitors by Total Liabilities
The table below lists competitors of Cleo Diagnostics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Century Casinos Inc
NASDAQ:CNTY
|
USA | $1.15 Billion |
|
Jack Chia Industries (Thailand) Public Company Limited
BK:JCT
|
Thailand | ฿196.38 Million |
|
Dacome International Ltd
TWO:9960
|
Taiwan | NT$389.18 Million |
|
B. Gaon Holdings Ltd
TA:GAON
|
Israel | ILA639.93 Million |
|
Opnet Technologies Co Ltd
TWO:8034
|
Taiwan | NT$137.78 Million |
|
Australian Vanadium Ltd
AU:AVL
|
Australia | AU$13.62 Million |
|
GiG Software PLC
ST:GIG-SDB
|
Sweden | Skr18.17 Million |
|
S. Khonkaen Foods Public Company Limited
BK:SORKON
|
Thailand | ฿1.88 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Cleo Diagnostics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see COV market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 8.30 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cleo Diagnostics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cleo Diagnostics Ltd (2022–2025)
The table below shows the annual total liabilities of Cleo Diagnostics Ltd from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.10 Million ≈ $779.55K |
+126.59% |
| 2024-06-30 | AU$486.22K ≈ $344.03K |
-75.93% |
| 2023-06-30 | AU$2.02 Million ≈ $1.43 Million |
+606.58% |
| 2022-06-30 | AU$285.89K ≈ $202.29K |
-- |
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more